利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.011 秒)

    USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER
    2.
    发明申请
    USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER 有权
    使用MYELOID细胞生物标记物进行癌症诊断

    公开(公告)号：US20120070461A1

    公开(公告)日：2012-03-22

    申请号：US13239011

    申请日：2011-09-21

    申请人： Harpreet SINGH ,  Regina MENDRZYK ,  Steffen WALTER ,  Vincenzo BRONTE ,  Susanna MANDRUZZATO

    发明人： Harpreet SINGH ,  Regina MENDRZYK ,  Steffen WALTER ,  Vincenzo BRONTE ,  Susanna MANDRUZZATO

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  G01N33/53

    CPC分类号： G01N33/57419 ,  G01N33/5047 ,  G01N33/5743 ,  G01N33/57438 ,  G01N33/57446

    摘要： The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

    摘要翻译： 本发明涉及骨髓细胞生物标志物用于肾细胞癌（RCC）或结肠直肠癌（CRC）的鉴别诊断，预后和监测的用途。 本发明还涉及监测针对肾细胞癌（RCC）或结肠直肠癌（CRC）的治疗效果，以及建立肾细胞癌（RCC）或结肠直肠癌（CRC）治疗结果的预后。 本发明还涉及用于上述方法的细胞生物标志物的面板，特别是用于测量所述生物标志物的多色面板。